The Paris Technology and Life Sciences team advised Meletios Therapeutics on its €2.8 million fund raising from family offices and business angels.
The French biotech company Meletios Therapeutics specializes in the research and development of next-generation antiviral treatments.
This fund raising is part of a €3.8 million global financing which also included two loans of €700k and €300k from Bpifrance. It allowed Meletios Therapeutics to finalize a proof-of-concept study for its first product and will help the Company to rapidly launch a first clinical trial, while pursuing the research and development of new innovative antiviral compounds.
The Goodwin team was led by Anne-Charlotte Rivière and included Johann Gandilhon on corporate aspects.
For more information, please read the press release.